Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur. He received his undergraduate training in English literature, psychology, and German literature at Yale College. Following this he completed his medical education at Harvard Medical School. After this his pediatric internship and residency were at Columbia University (New York, NY). He continued with post-doctoral fellowships in pediatric critical care, neonatal critical care, immunology, epithelial biology, and pediatric infectious disease at the Weizmann Institute of Science in (Rehovot, Israel), Children’s Hospital Medical Center (Boston, MA), the Massachusetts General Hospital (Boston, MA), the University of Massachusetts Medical Center (Worcester, MA), and Beth Israel Hospital Medical Center (Brookline, MA). Prior to his entrepreneurial career in biotechnology, he founded and led the Division of Critical Care Medicine at Children’s Hospital Medical Center (Cincinnati, OH), one of the largest pediatric critical care programs in North America.
Our Management Team
Dr. Southan is a nationally-renowned pharmaceutical development leader. A synthetic chemist by training, he has an extensive publication record and experience in nitric oxide (NO) synthase (NOS) and in the chemistry of NOS inhibitors, NO adducts, and NO donor compounds. He has spent 3 years with the Nobel Laureate Sir John R. Vane, FRS at the William Harvey Research Institute in London, England to study the biochemistry of NO and NO synthases.
Dr. Jagtap is a veteran medicinal chemist with 20 years of experience. He received his Ph.D. degree in Chemistry from University of Pune, India. He has played leading roles at several biotechnology and pharmaceutical firms resulting in the advancement of his patented technologies to the clinical stage of development. As a post-doctoral fellow at Virginia Tech, he discovered a series of new taxol derivatives, which showed greater potency than taxol and a semisynthetic analogue docetaxel.
Dr. Murthy is a veteran molecular biologist and biochemist, with more than 25 years experience in academia and the pharmaceutical industry. Among his scientific accomplishments, he reported in Nature the discovery, purification, characterization, cloning, and expression of novel RNA binding proteins from complex mixtures of cellular extracts.
Dr. Zsengeller is an expert on experimental histologic and immunohistochemical correlates of pathophysiology in various rodent and large animal experimental disease models. She also serves as an Instructor at Harvard Medical School in the Division of Molecular Medicine, Beth Israel Deaconess Medical Center (Boston, MA) where she studies inflammation, oxidative stress, and signaling pathways involved in kidney disease.
Dr. Cuzzocrea is the former President of the European Shock Society and a leader in the pathophysiology of experimental reperfusion injury and inflammation. Since his doctoral studies with Dr. Salzman in 1996 at Children’s Hospital Medical Center in Cincinnati, Professor Cuzzocrea has published more than 420 papers in international peer-reviewed journals, influencing the basic understanding of inflammatory and apoptotic reactions operative in ischemia reperfusion injury.
Dr. Garner is responsible for developing novel PK and PK/PD models to support discovery and development of small and large molecules. He has over 20 years of experience in PK and metabolism and has published numerous publications in pharmacokinetics and toxicokinetics of small molecules, human pharmacokinetic estimation, pharmacodynamics modeling, transporter interaction studies, metabolism, and P450 induction.